What RAC is all about is making sure we bring bisantrene back as quickly as possible to help patients and our shareholders. There is no one solution to cancer and no one company has all the answers. Our drug bisantrene was one of those unlucky drugs that slipped through the cracks. It may not be the cure for all cancers, but it has the potential to help million of cancer patients avoid the terrible side effects that come from cancer treatment, while also offering the potential of better treating their cancer (best of both worlds). We may not succeed, but it won't be due to a lack of effort on my part or any of the team at RAC.
I would encourage you to spend some more time learning about what we are doing these days - you might even find you like RAC. Not that it matters too much, but my name is Daniel Tillett - Tillbert sounds like Dilbert
RAC Price at posting:
$1.55 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)